SAS Output

DART ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

O
P
E
N
# COHORT NAME TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
# of
ACT.
INSTs
# of
CURR
IRBs
Open 1 Epithelial tumors of nasal cavity, sinuses, nasopharynx 4 4 3 1 1 0 344 149
Open 2 Epithelial tumors of major salivary glands 6 6 4 1 0 0    
Open 3 Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location 2 2 2 2 2 2    
Open 4 Undifferentiated carcinoma of gastrointestinal (GI) tract 1 1 1 0 0 0    
Open 5 Adenocarcinoma with variants of small intestine 9 9 4 4 3 0    
Open 6 Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) 2 2 0 0 0 0    
Closed 7 Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary 10 10 5 0 0 0    
Open 8 Rare Pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma 5 5 0 0 0 0    
Closed 9 Intrahepatic cholangiocarcinoma 9 9 1 0 0 0    
Closed 10 Extrahepatic cholangiocarcinoma and bile duct tumors 9 9 4 0 0 0    
Open 11 Sarcomatoid carcinoma of lung 0 0 0 0 0 0    
Open 12 Bronchoalveolar carcinoma lung (a.k.a. adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma) 0 0 0 0 0 0    
Open 13 Non-epithelial tumors of the ovary 9 9 8 4 3 0    
Open 14 Trophoblastic tumor 0 0 0 0 0 0    
Open 15 Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder 0 0 0 0 0 0    
Open 16 Cell tumor of the testes and extragonadal germ tumors 3 3 2 2 2 0    
Open 17 Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 0 0 0 0 0 0    
Open 18 Squamous cell carcinoma variants of the genitourinary (GU) system 0 0 0 0 0 0    
Open 19 Spindle cell carcinoma of kidney, pelvis, ureter 0 0 0 0 0 0    
Open 20 Adenocarcinoma with variants of GU system (excluding prostate cancer) 0 0 0 0 0 0    
Open 21 Odontogenic malignant tumors 0 0 0 0 0 0    
Open 22 Endocrine carcinoma of pancreas and digestive tract 2 2 1 1 1 1    
Open 23 Neuroendocrine carcinoma including carcinoid of the lung 22 22 14 9 9 2    
Open 24 Pheochromocytoma, malignant 2 2 1 0 0 0    
Open 25 Paraganglioma 2 2 1 0 0 0    
Open 26 Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex 4 4 3 1 1 0    
Open 27 Desmoid tumors 1 1 1 0 0 0    
Open 28 Peripheral nerve sheath tumors and NF1-related tumors 2 2 1 1 1 1    
Open 29 Malignant giant cell tumors 0 0 0 0 0 0    
Open 30 Chordoma 6 6 5 4 3 2    
Open 31 Adrenal cortical tumors 6 6 6 2 2 1    
Open 32 Tumor of unknown primary (Cancer of Unknown Primary; CuP) 16 16 9 7 6 1    
Open 33 Not Otherwise Categorized (NOC) Rare Tumors, after discussion with Study Chairs 29 29 22 11 9 2    
Closed 34 Adenoid cystic carcinoma 22 22 12 11 11 0    
Open 35 Vulvar cancer 1 1 1 1 1 1    
Open 36 MetaPLASTIC carcinoma (of the breast) 0 0 0 0 0 0    
Open 37 Gastrointestinal stromal tumor (GIST) 1 1 1 1 1 1    

CLOSED DART COHORTS AS OF 12-DEC-2017 6:10 AM

The REPORT Procedure

Detailed and/or summarized report

Table 1

O
P
E
N
# COHORT NAME TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
# of
ACT.
INSTs
# of
CURR
IRBs
Closed 7 Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary 10 10 5 0 0 0    
Closed 9 Intrahepatic cholangiocarcinoma 9 9 1 0 0 0    
Closed 10 Extrahepatic cholangiocarcinoma and bile duct tumors 9 9 4 0 0 0    
Closed 34 Adenoid cystic carcinoma 22 22 12 11 11 0